Edition:
India

GNC Holdings Inc (GNC.N)

GNC.N on New York Stock Exchange

4.36USD
16 Feb 2018
Change (% chg)

$-0.07 (-1.58%)
Prev Close
$4.43
Open
$4.43
Day's High
$4.59
Day's Low
$4.36
Volume
757,183
Avg. Vol
897,510
52-wk High
$10.95
52-wk Low
$3.13

Chart for

About

GNC Holdings, Inc. is a specialty retailer of health, wellness and performance products, which include protein, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty, food and drink and other general merchandise. The Company's operations consist of purchasing... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $586.09
Shares Outstanding(Mil.): 68.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 44.99 16.64
EPS (TTM): -- -- --
ROI: -- 5.13 10.66
ROE: -- 9.36 14.30

BRIEF-Harbin Pharma Scraps Plan For Unit To Bid For GNC's China Business

* SAYS CONTROLLING SHAREHOLDER SIGNS AGREEMENT TO BUY GNC HOLDINGS' CONVERTIBLE PREFERENCE SHARES WORTH $299.95 MILLION

14 Feb 2018

China's Harbin Pharma to buy stake in U.S. health retailer GNC

HONG KONG China's state-controlled drugmaker Harbin Pharmaceutical Group Holding Co will buy an about 40 percent stake in U.S. nutritional supplements retailer GNC Holdings Inc for $300 million and are in talks for a joint venture in China, the companies said.

14 Feb 2018

China's Harbin Pharma to buy stake in U.S. health retailer GNC

HONG KONG, Feb 14 China's state-controlled drugmaker Harbin Pharmaceutical Group Holding Co will buy an about 40 percent stake in U.S. nutritional supplements retailer GNC Holdings Inc for $300 million and are in talks for a joint venture in China, the companies said.

14 Feb 2018

BRIEF-GNC Holdings Says Launched Certain Amendments To Credit Agreement

* GNC HOLDINGS SAYS LAUNCHED CERTAIN AMENDMENTS TO CREDIT AGREEMENT DATED AS OF NOV 26, 2013​ - SEC FILING

14 Feb 2018

BRIEF-GNC Holdings Says On Deal Termination Co to Pay Termination Fee Of Either $10 Mln Or $18 Mln To Harbin Pharmaceutical

* GNC HOLDINGS - ON DEAL TERMINATION UNDER CIRCUMSTANCES, CO WILL PAY FEE OF EITHER $10 MILLION OR $18 MILLION TO HARBIN PHARMACEUTICAL GROUP - SEC FILING Source text: (http://bit.ly/2o4g6KY) Further company coverage:

14 Feb 2018

BRIEF-GNC And Harbin Pharmaceutical Announce $300 Mln Strategic Investment

* GNC AND HARBIN PHARMACEUTICAL ANNOUNCE $300 MILLION STRATEGIC INVESTMENT AND CHINA JOINT VENTURE

13 Feb 2018

BRIEF-GNC Holdings Q4 Loss Per Share $2.99

* GNC HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

13 Feb 2018

BRIEF-GNC Holdings Sees Q4 Adj Diluted Earnings Per Share To Be $0.24 To $0.25

* SEES AN INCREASE IN Q4 SAME STORE SALES FOR DOMESTIC COMPANY-OWNED STORES (INCLUDING GNC.COM SALES) OF 5.7%

18 Jan 2018

Fitch Downgrades GNC's IDR to 'RD' / Upgrades IDR to 'CCC' on Completion of Debt Exchange

(The following statement was released by the rating agency) NEW YORK, December 29 (Fitch) Fitch Ratings has downgraded GNC Holdings, Inc.'s Long-Term Issuer Default Rating (IDR) to 'RD' from 'C' following the Dec. 27 closing of its distressed debt exchange (DDE) for approximately $99 million of its $288 million in convertible notes for approximately 14.6 million shares (or approximately 17%) of its common equity, valued at around $50 million. Subsequently, Fitch upgraded GNC's Long-Term IDR to '

29 Dec 2017

Fitch Downgrades GNC to 'C' on Distressed Debt Exchange Announcement

(The following statement was released by the rating agency) NEW YORK, December 22 (Fitch) Fitch Ratings has downgraded GNC Holdings, Inc.'s Issuer Default Rating (IDR) to 'C' from 'B-' following the company's announcement that it will be exchanging approximately $99 million of its $288 million of convertible notes due August 2020 for approximately 14.6 million shares (approximately 17% of pro forma share count or around $55 million in value), given Fitch's view that this represents a distressed

23 Dec 2017

Competitors

  Price Chg
SHAKLEE GLOBAL GROUP,INC. (8205.T) ¥10,340 -130.00
Kenko.com,Inc. (3325.T) -- --

Earnings vs. Estimates